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chance per day of no longer needing supplementary oxygen 
was reduced (hazard rate 0.84; 0.76–0.93). No effect was ob-
served for need of surfactant treatment (odds ratio 1.08; 
0.91–1.28). Hardy-Weinberg equilibrium was unlikely for the 
cohort (p < 0.012). This could be explained by death prior to 
genotype sampling. In tests of robustness this failed to ex-
plain the primary results.  Conclusions: Compared to the 
common genotype, UGT1A1 * 28 genotypes were associated 
with an increased need of oxygen supplementation and risk 
of BPD in very preterm newborns.  © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Oxidative stress is thought to be involved in respira-
tory disease amongst preterm infants, and antioxidants 
may accordingly be important in its prevention  [1, 2] .
 Bilirubin is neurotoxic, but it is also an antioxidant of 
possible clinical relevance  [3] . The association between 
bilirubin and respiratory disease in the preterm popula-
tion has been explored in previous observational studies 
and as a secondary outcome in an interventional study, 
with diverging results  [4–6] . The challenges in noninter-
ventional studies of bilirubin’s influence on neonatal out-
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 Abstract 
 Background: Respiratory disease in the very preterm infant 
is frequent and often severe. Bilirubin is both a potent neu-
rotoxin and antioxidant, and may have a clinical impact on 
preterm respiratory disease. The Gilbert genotype, the
UGT1A1 * 28 allele, is the major known genetic cause of vari-
ation in bilirubin.  Objectives: To study the association be-
tween respiratory disease in the very preterm infant and the 
UGT1A1 * 28 allele.  Methods: This is a cohort study of 1,354 
very preterm infants (gestational age <32 weeks) born in Jut-
land, Denmark in 1997–2011. Genotypes were obtained 
from the Danish Neonatal Screening Biobank, and clinical in-
formation was obtained from the databases of two tertiary 
neonatal intensive care units. Outcomes were the need for 
surfactant therapy, any need for and duration of supple-
mentary oxygen and bronchopulmonary dysplasia (BPD). 
 Results: Per UGT1A1 * 28 allele, odds were increased for any 
need of supplementary oxygen (odds ratio 1.26; 1.05–1.50) 
and for BPD (odds ratio 1.71; 1.23–2.39), the need of supple-
mentary oxygen increased by 6.38 days (1.87–10.89), and 
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comes are the possibility of reverse causality and the pres-
ence of potential confounding factors. One way of ad-
dressing these challenges is by utilizing the genotype of 
Gilbert-Meulengracht syndrome, the UGT1A1 * 28 allele 
 [7] .
 The rate-limiting enzyme in the metabolism of biliru-
bin is hepatic uridine diphosphate glucuronosyltransfer-
ase 1A1 (UGT1A1)  [8] . In the UGT1A1 * 28 allele an extra 
TA pair is inserted in the TATA box of the UGT1A1 gene, 
reducing the activity of hepatic UGT1A1 by approxi-
mately 30% per allele. The allele is the major known ge-
netic cause of variation in plasma bilirubin in adult West-
ern European populations, accounting for approximately 
18% of all variations  [8–10] . In the term neonatal popula-
tion, the allele has been associated with accelerated devel-
opment and duration of hyperbilirubinemia, while the as-
sociation with crossing of treatment thresholds is uncer-
tain  [11–13] . No data exist for the preterm population.
 Mendel’s second law states that alleles are inherited 
randomly at conception. As genotypes are permanent, es-
timates of the association between UGT1A1 * 28 geno-
types and respiratory outcomes will be unconfounded, 
and thus the possibility of reverse causality is eliminated 
 [9, 14] . To test the effect of genetically elevated bilirubin, 
we investigated the association between UGT1A1 * 28 
genotypes and respiratory disease in a cohort of 1,354 
very preterm infants.
 Subjects and Methods 
 The study setting was two regions in Jutland, Denmark (1997–
2011), with a population of 1.3 million people and some 21,000 live 
births per year. The study units were the two regional tertiary neo-
natal intensive care units (NICUs).
 In Denmark, the first choice of respiratory support is nasal con-
tinuous positive airway pressure, with surfactant provided as res-
cue treatment to preterm infants with respiratory distress syn-
drome, according to nationally uniform criteria as described by 
Verder et al.  [15] . During the study period, the two units used 
supplementary oxygen, targeting saturations at 88–92%.
 The neonatal database of the two tertiary NICUs provided data 
on birth weight, gestational age (best obstetric estimate), date of 
last day with oxygen supplementation (if any) and date of dis-
charge  [16] . The database does not hold information on bilirubin 
measures or phototherapy. The study population was restricted to 
primary admissions at a study NICU within the first 24 h of life, 
gestational age <32 weeks, birth weight <2,000 g and no life-threat-
ening malformations. Follow-up ended at first discharge from the 
tertiary NICU or death.
 At birth, Danish citizens are assigned a unique 10-digit civil 
registration (CPR) number, which allows unambiguous individu-
al-level identification and data linkage across nationwide registers 
and hospital records  [17] . The parent’s country of birth and the 
present status of the child (alive, dead or emigrated, and date of 
death if relevant) were obtained from the Danish CPR register  [17] . 
The date of birth and sex of the infant can be unambiguously de-
rived from the CPR number.
 As part of the Danish national neonatal screening program for 
metabolic diseases, a dried blood spot sample is collected routine-
ly from all newborns shortly after birth. The excess dried blood 
spot material is stored in the Danish Neonatal Screening Biobank, 
which covers about 99% of all newborns  [18] . In the study units, 
dried blood spot sampling amongst the very preterm was delayed 
until 28 days’ postnatal age for most of the study period, and there-
fore preterm nonsurvivors are rarely present in the Biobank.
 The dried blood spots of the cohort were identified in the Bio-
bank by the use of the CPR numbers. DNA was extracted and sub-
sequently whole-genome amplified, as previously described  [19] . 
Genotyping was performed at LGC Genomics (Teddington, UK) 
using a custom-made competitive allele-specific PCR genotyping 
assay. Genotyping was executed jointly with two other studies (to-
tal n = 4,147), and the laboratory was unaware of individual sample 
identities, project belongings and the type and the aim of the proj-
ects. In a subsample of the studies (n = 648), genotyping was also 
performed at Statens Serum Institut (Copenhagen, Denmark), us-
ing the pyrosequencing platform (Qiagen, Hilden, Germany)  [20] . 
The concordance rate between the genotypes produced by com-
petitive allele-specific PCR compared to pyrosequencing was 
99.8%.
 Statistical Methods 
 We used STATA version 12.1 (StataCorp, College Station, Tex., 
USA) for statistical analyses. In the primary analyses, UGT1A1 * 28 
genotypes were treated as a continuous variable (common geno-
type = 0, heterozygotes = 1, homozygotes = 2) and in secondary 
analyses as a categorical variable in three groups, with common 
genotype as the reference.
 Dichotomous estimates of respiratory disease were any need of 
additional oxygen, need of surfactant therapy and bronchopulmo-
nary dysplasia (BPD) defined as the need of supplemental oxygen 
at 36 postmenstrual weeks. Infants who left the study prior to this 
age were included as not having BPD if supplementary oxygen was 
discontinued at least 1 day prior to discharge; infants leaving the 
study with oxygen supplementation prior to 36 postmenstrual 
weeks’ gestational age were excluded. Dichotomous associations 
are reported as odds ratios (OR) from logistic regression analysis.
 The continuous variable related to respiratory disease was time 
with supplementary oxygen (days) and was estimated as hazard 
ratios (HR) for discontinuation of supplementary oxygen using 
Cox regression analysis, and the absolute difference in the number 
of days with supplementary oxygen was estimated using general-
ized linear methods with pseudo values  [21] . The time scale was 
days from birth, and the event was discontinuation of supplemen-
tary oxygen. Censoring occurred if the infant left the unit or died.
 In all analyses, siblings were treated as clusters based on the 
maternal CPR number. All analyses were adjusted for African her-
itage as a continuous covariate (parent born in Africa: no = 0,
one = 1, both = 2), sex and year of birth as a categorical covariate 
(1997–2001, 2002–2006 and 2007–2011).
 Hardy-Weinberg equilibrium (HWE) was estimated using the 
‘ hwsnp  command’. Spearman’s rank correlation was used to evalu-
ate genotype distributions across four gestational age groups (24–
25 weeks, 26–27 weeks, 28–29 weeks and 30–31 weeks).
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 Death and BPD/discontinuation of supplementary oxygen 
were competing outcomes, and the majority of infants who died 
were not in the Biobank. As this could potentially cause immortal 
person-time bias in our study, we performed two tests of robust-
ness for primary results. Continuous outcomes were re-examined 
with the use of a time scale of days from 28 days’ postnatal age, the 
routine day of metabolic screening for very preterm infants in the 
two NICUs and thus the presumed day of study entry. Further-
more, all analyses were repeated and stratified into infants with a 
high mortality and low mortality, corresponding to gestational 
ages of 24–28 weeks and 29–31 weeks. All estimates are reported 
with 95% confidence intervals.
 Ethics 
 The study was approved by the regional Ethics Committees on 
Human Studies (J.nr. 1-10-72-363-12), the Danish Data Protec-
tion Agency (J.nr. 1-16-02-153-12) and the Danish Neonatal Bio-
bank Steering Committee, and conducted according to the prin-
ciples of the Declaration of Helsinki.
 Results 
 The 1,773 infants who fulfilled the criteria for study 
entry were identified in the neonatal database. For 1,354 
of these, the genotype and information on supplementary 
oxygen were available. A total of 159 infants died before 
the 28-day postnatal cutoff, and a genotype was not avail-
able in 132 of these infants.
 The basic characteristics of the study cohort are shown 
in  table 1 . Of the 1,354 infants, 920 received supplemen-
tary oxygen for at least 1 day. Per UGT1A1 * 28 allele, we 
found an unadjusted increase in odds for any need of sup-
plementary oxygen of 24% (OR 1.24; 1.04–1.48), for sur-
factant treatment of 10% (OR 1.10; 0.93–1.30) and for 
BPD of 73% (OR 1.73; 1.24–2.40). Per allele, the chance 
of being weaned off oxygen at any given day was 16% 
lower (HR 0.84; 0.76–0.93), and the need of supplemen-
tary oxygen increased by 6.49 days (2.1–10.9). Adjust-
ment for infant sex, year of birth and African ethnicity 
had almost no effect on the estimates ( table 2 ). Analyses 
of genotype as a categorical variable gave similar results 
(data not shown).
 HWE was unlikely for the study cohort (p < 0.012) and 
also for the part of the cohort in which both parents were 
born in Denmark (p < 0.005). To assess whether excess 
mortality prior to dried blood spot sampling may explain 
some of the deviation from HWE, we used gestational age 
in four groups as a proxy variable for likelihood of death. 
UGT1A1 * 28 genotypes were more frequent in the high 
mortality/low gestational age stratums, and this distribu-
tion was unlikely to be caused by chance (p < 0.005;  table 3 ).
 The association between genotype and respiratory 
support stratified by a proxy variable for high and low 
mortality (24–28 weeks’ gestational age and 29–31 weeks’ 
gestational age) was estimated (online suppl. material; see 
www.karger.com/doi/10.1159/000442042). Overall, the 
estimates were smaller for all respiratory outcomes in the 
higher gestational age/low mortality stratum. However, 
the results between the two strata were quite similar.
 Of the original 1,773 infants in the cohort, 1,614 were 
alive at 28 postnatal days. Data on genotype and oxygen 
treatment were available in 1,343 of these, of whom 366 
received oxygen at that time and thus could enter the 
analysis of continuous outcomes. Seventeen infants died 
after 28 days, but in only 3 of these was the dried blood 
spot missing.
 With days from the 28th day after birth as the time 
frame, we found (unadjusted per allele) that the chance of 
being weaned from oxygen any day decreased by 14% (HR 
0.86; 0.73–1.00) and that 4.98 extra days of extra oxygen 
was needed (–0.63 to 10.58). Again, adjustment for infant 
sex, year of birth and African ethnicity left estimates al-
most unchanged. Fully adjusted estimates for these analy-
ses for UGT1A1 * 28 heterozygotes and homozygotes are 
given in  table 4 . When genotype was considered a categor-
ical variable, the results were similar (data not shown).
Boys, % 53
Gestational age, weeks1 29 (25 – 31)
Birth weight, g1 1,190 (665 – 1,815)
Surfactant treatment, % 40
Any need of supplementary oxygen, % 68
Duration of supplementary oxygen treatment, days1 8 (0 – 75)
BPD, % 7
African (none/1 parent/both parents), n 1,318/14/22
BPD is defined as the need of supplementary oxygen at 36 weeks’ postmenstrual age.
1 Data are presented as medians (with 5 – 95 percentile range).
 Table 1.  Basic clinical characteristics of 
1,354 consecutive very preterm infants 
with UGT1A1 genotyping from the Mid 
and Northern Regions of Jutland,
Denmark, 1996 – 2011
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 Discussion 
 Key Results 
 In this study, we examined the association between 
UGT1A1 * 28 genotypes and respiratory morbidity in a 
cohort of very preterm children. We found that
UGT1A1 * 28 genotypes were associated with increased 
odds for any need of supplementary oxygen, a prolonged 
need of supplementary oxygen and an increased risk of 
BPD in preterm survivors. Preterm infants with
UGT1A1 * 28 genotypes had the same need for surfactant 
treatment as those with the common genotype.
 HWE was unlikely for the cohort. This prompted a 
sensitivity analysis whereby we found that UGT1A1 * 28 
genotypes were more prevalent in the extremely preterm 
infants than among the less preterm, the increased preva-
lence seemingly being associated with death prior to ge-
notype sampling. In two tests of robustness, this associa-
tion did not explain the primary estimates.
 Table 2.  The association between UGT1A1*28 genotypes and respiratory morbidity for 1,354 very preterm infants
Surfactant 
treatment,
OR (95% CI)
Any need of 
oxygen,
OR (95% CI)
Cessation of supple-
mentary oxygen,
HR (95% CI)
Duration of oxygen
treatment,
difference days (95% CI)
BPD,
OR (95% CI)
Common genotype Ref. Ref. Ref. Ref. Ref.
UGT1A1*28 heterozygous 1.08 (0.91 – 1.28) 1.25 (1.05 – 1.50) 0.84 (0.76 – 0.93) 6.38 (1.87 – 10.89) 1.71 (1.23 – 2.39)
UGT1A1*28 homozygous 1.17 (0.83 – 1.64) 1.57 (1.10 – 2.24) 0.71 (0.58 – 0.87) 12.75 (3.73 – 21.78) 2.93 (1.51 – 5.70)
 All analyses were adjusted for sex, birth year and African race. OR were estimated by conditional logistic regression, HR by Cox re-
gression analysis and numeric difference in days with oxygen by generalized linear methods with pseudo values. BPD is defined as the 
need of supplementary oxygen at 36 weeks’ postmenstrual age.
 Table 3.  Distribution of UGT1A1*28 genotypes and neonatal mortality on 4 gestational age strata for a cohort of very preterm infants
Gestational age,
weeks
Common genotype,
% (n)
UGT1A1*28 heterozygotes,
% (n)
UGT1A1*28 homozygotes,
% (n)
Mortality,
%
24 – 25 41.7 (53) 45.7 (58) 12.6 (16) 38.3 
26 – 27 43.5 (128) 42.2 (124) 14.3 (42) 14.9
28 – 29 51.3 (210) 38.1 (156) 10.5 (43) 5.0
30 – 31 52.2 (282) 38.5 (208) 9.3 (50) 1.8
 Genotypes are given for the 1,354 infants in the study cohort. Neonatal mortality rates are reported for all the 1,773 infants who would 
have been in the cohort had dried blood spot samples been available – due to timing of sampling 83% were missing for children who 
died prior to 28 days’ postnatal age.
 Table 4.  Estimates of association between UGT1A1*28 genotypes and time with supplementary oxygen ≥28 days after birth for 1,343 
preterm infants, born at 24 – 31 weeks’ gestational age and still alive 28 days after birth
Cessation of supplementary oxygen,
HR (95% CI)
Duration of oxygen treatment,
difference days (95% CI)
Common genotype Ref. Ref.
UGT1A1*28 heterozygotes 0.84 (0.71 to 1.00) 5.28 (–0.18 to 10.73)
UGT1A1*28 homozygotes 0.70 (0.50 to 0.99) 10.55 (–0.36 to 21.46)
 All analyses were adjusted for birth year, sex and African race. HR were estimated by Cox regression and numeric difference in days 
with oxygen by generalized linear methods with pseudo values. 
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 Strengths and Limitations 
 Strengths 
 A major strength of our study is the availability of clin-
ical data and genotypes covering more than a decade for 
a well-defined population. By combining the clinical in-
formation from two tertiary NICUs serving a specific 
geographical area with the biological data at the Danish 
Neonatal Screening Biobank, we were able to study the 
association between UGT1A1 * 28 genotypes and respira-
tory morbidity for a large cohort of very preterm infants.
 Limitations 
 HWE was unlikely for the cohort. This implies one of 
the following: genotyping is flawed, population stratifica-
tion is present or selection upon the tested genotype has 
taken place  [22] . Our genotyping was performed at the 
same time as two control series (some 400 and 1,500 con-
trols, respectively), and none of these showed evidence 
against HWE  [11, 23] . Furthermore, we tested a subsam-
ple in two different laboratories with two different meth-
ods and found no difference in genotypes.
 The Danish population is genetically very homoge-
neous, and in a sensitivity test, ethnic heterogeneity failed 
to explain the lack of HWE. Thus, selection may be the 
most likely cause of the deviation from HWE. The study 
cohort was selected toward survivors, and UGT1A1 * 28 
genotypes increased with decreasing gestational age and 
increasing mortality. It is possible that fetuses with the 
UGT1A1 * 28 genotypes are more prone to be born pre-
term, but our data may also suggest ex utero selection and 
an increased chance of survival in preterm infants with 
UGT1A1 * 28 genotypes.
 As death and BPD/cessation of supplementary oxy-
gen are competing outcomes, an association between 
UGT1A1 * 28 genotypes and survival could cause immor-
tal person-time bias in our estimates  [24] . A recommend-
ed approach to avoid immortal person-time bias is to ex-
clude the immortal time from the denominator  [24] . We 
did so in a test of robustness by only including risk time 
after 28 days’ postnatal age, and the results were essen-
tially unchanged. In addition, our results also remained 
essentially unchanged after stratification according to 
gestational age (a proxy variable for the risk of early 
death). Accordingly, immortal person-time bias is un-
likely to explain our results.
 We adjusted for African heritage due to a higher fre-
quency of UGT1A1 * 28 genotypes and a lower neonatal 
morbidity in this population  [10, 25] . Few infants of Af-
rican heritage were present in the cohort, and the adjust-
ment made no difference to our results.
 Interpretation 
 The UGT1A1 enzyme metabolizes a variety of other 
endogenous and exogenous substances apart from biliru-
bin  [10] . Also, the association between UGT1A1 * 28 ge-
notypes and plasma bilirubin is well established in adults, 
but no data for preterm infants exist. Thus, it is very pos-
sible that metabolites other than bilirubin may play a role 
in the association between UGT1A1 * 28 genotypes and 
preterm respiratory morbidity.
 Morris et al.  [5] published a large randomized trial of 
two thresholds of serum bilirubin for phototherapy in 
very preterm infants. In the secondary analyses, they 
found that a higher treatment threshold, and thus higher 
overall bilirubin levels, was associated with a higher risk 
of BPD. This is in accordance with our findings.
 A decreased respiratory drive due to a direct effect on 
the central nervous system of higher levels of bilirubin 
may be one potential explanation of these findings. A pre-
vious study has shown an association between hyperbili-
rubinemia and the risk of apnea and bradycardia in pre-
term infants  [26] . Furthermore, analyses from the trial by 
Morris et al.  [5] showed neurotoxic effects from plasma 
bilirubin levels at higher treatment thresholds.
 We found no association between UGT1A1 * 28 geno-
types and the need of rescue surfactant in the very pre-
term infants. This is in line with data that suggest that 
UGT1A1 activity is very low in the preterm infant imme-
diately after birth and, therefore, that no effect of the ge-
notype in the first days of life is to be expected  [27] .
 In preterm infants with birth weights of 501–750 g, 
Morris et al.  [5] found that a high phototherapy treatment 
threshold (a high bilirubin level) was associated with in-
creased survival. This could be in accordance with our 
observation of an increased frequency of UGT1A1 * 28 
genotypes amongst the most preterm surviving infants if 
bilirubin is the causative metabolite in our study.
 Conclusion 
 Compared to the common genotype, UGT1A1 * 28 
genotypes were associated with an increased need of oxy-
gen supplementation and risk of BPD in preterm new-
borns.
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